Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
We previously reported that lysophosphatidic acid (LPA) initiates nerve injury-induced neuropathic pain and its underlying mechanisms. In addition, we recently demonstrated that intrathecal injection of LPA induces de novo LPA production through the action of autotaxin (ATX), which converts lysophosphatidylcholine to LPA. Here, we examined nerve injury-induced de novo LPA production by using a highly sensitive biological titration assay with B103 cells expressing LPA1 receptors. Nerve injury caused high levels of LPA production in the ipsilateral sides of the spinal dorsal horn and dorsal roots, but not in the dorsal root ganglion, spinal nerve, or sciatic nerve. Nerve injury-induced LPA production reached its maximum at 3 h after injury, followed by a rapid decline by 6 h. The LPA production was significantly attenuated in ATX heterozygous mutant mice, whereas the concentration and activity of ATX in cerebrospinal fluid were not affected by nerve injury. On the other hand, the activities of cytosolic phospholipase A2 (cPLA2) and calcium-independent phospholipase A2 (iPLA2) were enhanced, with peaks at 1 h after injury. Both de novo LPA production and neuropathic pain-like behaviors were substantially abolished by intrathecal injection of arachidonyl trifluoromethyl ketone, a mixed inhibitor of cPLA2 and iPLA2, or bromoenol lactone, an iPLA2 inhibitor, at 1 h after injury. However, administration of these inhibitors at 6 h after injury had no significant effect on neuropathic pain. These findings provide evidence that PLA2- and ATX-mediated de novo LPA production in the early phase is involved in nerve injury-induced neuropathic pain.
Ma
Lin
L
Division of Molecular Pharmacology and Neuroscience, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Uchida
Hitoshi
H
Nagai
Jun
J
Inoue
Makoto
M
Aoki
Junken
J
Ueda
Hiroshi
H
D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D015153:Blotting, Western; D002460:Cell Line; D007278:Injections, Spinal; D008244:Lysophosphatidylcholines / Q000378:metabolism; D008246:Lysophospholipids / Q000096:biosynthesis* / Q000502:physiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009097:Multienzyme Complexes / Q000378:metabolism / Q000502:physiology*; D009281:Naphthalenes / Q000494:pharmacology; D009437:Neuralgia / Q000378:metabolism*; D010147:Pain Measurement; D043264:Phosphodiesterase I / Q000378:metabolism / Q000502:physiology*; D064801:Phospholipase A2 Inhibitors; D054467:Phospholipases A2 / Q000378:metabolism / Q000502:physiology*; D010727:Phosphoric Diester Hydrolases; D020671:Posterior Horn Cells / Q000378:metabolism / Q000503:physiopathology; D011753:Pyrones / Q000494:pharmacology; D011755:Pyrophosphatases / Q000378:metabolism / Q000502:physiology*; D012584:Sciatic Nerve / Q000293:injuries; D013126:Spinal Nerve Roots / Q000378:metabolism / Q000503:physiopathology; D000099189:Lysophospholipase D
D001095:Arachidonic Acids; D008244:Lysophosphatidylcholines; D008246:Lysophospholipids; D009097:Multienzyme Complexes; D009281:Naphthalenes; D043264:Phosphodiesterase I; D064801:Phospholipase A2 Inhibitors; D054467:Phospholipases A2; D010727:Phosphoric Diester Hydrolases; D011753:Pyrones; D011755:Pyrophosphatases; D000099189:Lysophospholipase D; C081565:arachidonyltrifluoromethane; C068314:6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; C032881:lysophosphatidic acid